Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07088068 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 723
- Enrollment target
- 20
- Study locations
NCT07088068 is a Phase 3 study of Type 1 Diabetes Mellitus that is actively recruiting participants, run by Sanofi. The registered enrollment target is 723 participants, above the 133-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (444% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT07088068, a Phase 3 study of Type 1 Diabetes Mellitus, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 723 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) aged 1 to 25 years, on standard insulin therapy.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Teplizumab
Study Locations (20)
Florida
- University of Florida College of Medicine- Site Number : 8400054 - Gainesville
- Encore Medical Research - Hollywood- Site Number : 8400061 - Hollywood
- University of South Florida- Site Number : 8400013 - Tampa
Georgia
- Atlanta Diabetes Associates- Site Number : 8400036 - Atlanta
- IACT Health - Columbus - Talbotton Road- Site Number : 8400003 - Columbus
- Institute of Endocrinology Diabetes, Health & Hormones- Site Number : 8400050 - Stockbridge
New York
- University at Buffalo - Jacobs School of Medicine- Site Number : 8400006 - Buffalo
- Endocrine Associates of West Village- Site Number : 8400064 - New York
- Columbia University Irving Medical Center- Site Number : 8400009 - New York
California
- Marvel Clinical Research- Site Number : 8400042 - Huntington Beach
- University of California San Francisco - Mission Bay- Site Number : 8400011 - San Francisco
Idaho
- St. Luke's Children's Hospital- Site Number : 8400014 - Boise
- Rocky Mountain Clinical Research - Idaho Falls- Site Number : 8400001 - Idaho Falls
Arizona
- Scottsdale Clinical Trials- Site Number : 8400044 - Scottsdale
Colorado
- Barbara Davis Center for Childhood Diabetes- Site Number : 8400031 - Aurora
Connecticut
- Yale University School of Medicine- Site Number : 8400005 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 723 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2028-12-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07088068
The ClinicalTrials.gov registry entry for NCT07088068 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 723 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 133-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (444% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07088068 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT07088068 about?
NCT07088068 is a clinical study titled "A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes". This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment. The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenou...
What is the current status of trial NCT07088068?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 723 participants. The study started on 2025-08-06. Estimated completion is 2028-12-12.
What conditions does trial NCT07088068 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT07088068?
The interventions under investigation include: Placebo (OTHER), Teplizumab (DRUG).
Who is sponsoring clinical trial NCT07088068?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07088068 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
-
Efficacy of Islet After Kidney Transplantation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.